Prothena price target raised to $38 from $30 at RBC Capital RBC Capital increased its price target on Prothena (PRTA) after the company announced a worldwide partnership with Roche (RHHBY) on PRX-002 for Parkinson's disease. The firm thinks the deal creates potential value on an asset that previously was given little credit, while validating Prothena's expertise. The firm keeps an Outperform rating on the shares.
News For PRTA From The Last 14 Days
Check below for free stories on PRTA the last two weeks.